Omeros Corporation
$13.47
▼
-9.77%
2026-04-21 08:38:00
www.omeros.com
NGM: OMER
Explore Omeros Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$997.87 M
Current Price
$13.47
52W High / Low
$17.65 / $2.95
Stock P/E
—
Book Value
$-1.69
Dividend Yield
—
ROCE
-49.6%
ROE
2.21%
Face Value
—
EPS
$-0.08
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
175
Beta
2.53
Debt / Equity
-1.97
Current Ratio
2.76
Quick Ratio
2.76
Forward P/E
8.35
Price / Sales
—
Enterprise Value
$905.27 M
EV / EBITDA
-7.43
EV / Revenue
—
Rating
Buy
Target Price
$38
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Vor Biopharma Inc. | $15.71 | — | $810.38 M | — | -84.67% | 2057.65% | $65.8 / $2.62 | $-8.1 |
| 2. | SciSparc Ltd. | $4.23 | — | $2.5 M | — | -80.93% | -12.81% | $94.5 / $2.98 | $142.32 |
| 3. | Filana Therapeutics, Inc. | $1.75 | — | $84.54 M | — | -128.99% | -82.66% | $2.27 / $1.53 | $1.54 |
| 4. | Incyte Corporation | $97.69 | 15.26 | $19.46 B | — | 24.67% | 29.87% | $112.29 / $56.13 | $26.04 |
| 5. | Metagenomi Therapeutics, Inc. | $1.53 | — | $55.68 M | — | -48.45% | -44.66% | $3.95 / $1.25 | $4.22 |
| 6. | Zentalis Pharmaceuticals, Inc. | $4.03 | — | $301.33 M | — | -57.45% | -49.54% | $6.95 / $1.13 | $3.13 |
| 7. | Minerva Neurosciences, Inc. | $6.89 | — | $289.51 M | — | -15.79% | 352.58% | $12.46 / $1.3 | $-3.25 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -29.08 M | -26.39 M | -32.35 M | -34.97 M | -35.66 M | — |
| Net Profit | 86.45 M | -30.92 M | -25.42 M | -33.46 M | -31.36 M | — |
| EPS in Rs | 1.2 | -0.43 | -0.35 | -0.46 | -0.44 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -122.8 M | -166.95 M | -164.53 M | -163.39 M |
| Net Profit | -3.35 M | -156.81 M | -117.81 M | 47.42 M |
| EPS in Rs | -0.05 | -2.18 | -1.64 | 0.66 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 325.63 M | 277.08 M | 378.27 M | 590.97 M |
| Total Liabilities | 446.86 M | 459.69 M | 403.25 M | 505.29 M |
| Equity | -121.23 M | -182.61 M | -24.98 M | 85.68 M |
| Current Assets | 215.67 M | 134.12 M | 217.9 M | 443.24 M |
| Current Liabilities | 78.06 M | 79.53 M | 53.32 M | 136.38 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -116.09 M | -148.8 M | 74.73 M | -86.48 M |
| Investing CF | 164.52 M | 82.22 M | 27.45 M | -127.56 M |
| Financing CF | -42.17 M | 62.88 M | -106.08 M | 124.25 M |
| Free CF | -116.16 M | -148.97 M | 74.3 M | -86.6 M |
| Capex | -0.07 M | -0.17 M | -0.43 M | -0.11 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -33.11% | -348.46% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.